May 26, 2022 News by Marisa Wexler, MS Ponvory Reduces Risk of Worsening Disability Over Placebo Treatment with Ponvory (ponesimod) significantly reduces the risk of worsening disability or new relapses for people with relapsing forms of multiple sclerosis (MS) compared with a placebo, according to a new analysis funded by the therapy’s maker Janssen. The study,Ā “Comparative Efficacy of Relapsing Multiple Sclerosis Therapies:…
December 29, 2021 News by Yedida Y Bogachkov PhD NHS England and Wales to Offer Ponvory at Low or No Cost for RRMS Note: This story was updated Jan. 12, 2022, to note that Ponvory is approved in the U.K. for people with relapsing forms of MS who have active disease, defined by clinical or imaging features. The National Institute for Health and Care Excellence (NICE) has recommended thatĀ Ponvory (ponesimod)…
November 12, 2021 News by Patricia Inacio, PhD Ponvory Now Available in Scotland at Low or No Cost Through NHS TheĀ Scottish Medicines ConsortiumĀ (SMC)Ā has recommended thatĀ Ponvory (ponesimod) be offered through the National Health Service (NHS) Scotland to people with active, relapsing forms of multiple sclerosisĀ (MS). The decision means that the oral therapy will be available at low or no cost to patients with clinically isolated syndrome (CIS),…
October 13, 2021 News by Marisa Wexler, MS #ECTRIMS2021 ā Ponvory Effective in Early MS in OPTIMUM Trial Editorās note: TheĀ Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13ā15. GoĀ hereĀ to see the latest stories from the conference.
October 11, 2021 News by Patricia Inacio, PhD NICE Opposes Ponvory Being Added to NHS for England and Wales The National Institute for Health and Care Excellence (NICE) will not recommend that Ponvory (ponesimod) be added to the National Health Service (NHS) of England and Wales for people with active, relapsing forms of multiple sclerosis (MS). The provisional decision, made because Ponvory was not found to be…
June 21, 2021 News by Marisa Wexler, MS Results: Ponvory Outperforms Aubagio in OPTIMUM Clinical Trial In the OPTIMUM clinical trial,Ā Ponvory (ponesimod) significantly outperformed Aubagio (teriflunomide) in reducing relapse rates, fatigue, and evidence of brain damage among people with relapsing multiple sclerosis (MS). Based on these results, Ponvory has now been approved in the U.S. and the European Union as a treatment…
May 25, 2021 News by Forest Ray PhD Ponvory Approved in EU for Active Relapsing Forms of MS The European Commission has approved PonvoryĀ (ponesimod) to treat adults with relapsing forms of multiple sclerosis (MS) and active disease, as defined by clinical or imaging features. The approval, which follows a recommendation from the Committee for Medicinal Products for Human Use in March, covers clinically isolated…
March 29, 2021 News by Forest Ray PhD Ponvory Recommended for Approval in EU for Relapsing Forms of MS A branch of the European Medicines Agency has recommended that PonvoryĀ (ponesimod) be approved to treat relapsing forms of multiple sclerosisĀ (MS) in adults with active disease. This positive opinion from agency’s Committee for Medicinal Products for Human Use (CHMP) covers clinically isolated syndrome,Ā relapsing-remitting MSĀ (RRMS), andĀ active secondary…
March 19, 2021 News by Marisa Wexler, MS Ponvory (ponesimod) Approved for Adults With Relapsing Forms of MS The U.S. Food and Drug Administration (FDA) has approved Ponvory (ponesimod) as an oral treatment for adults with relapsing forms of multiple sclerosis (MS). The approval covers clinically isolated syndrome, relapsing-remitting MS (RRMS), and active secondary progressive MS (SPMS). The treatment is taken as a…
September 22, 2020 News by Marta Figueiredo, PhD Gilenya Remains Favorite S1P Receptor Modulator in US, But Zeposia May Catch Up, Survey Finds Among oral sphingosine-1-phosphate (S1P) receptor modulators for multiple sclerosis (MS), Novartisās GilenyaĀ (fingolimod) remains physiciansā favorite in the U.S., but prescriptions of recently-launched Bristol Myers Squibbās Zeposia (ozanimod) are beginning to rise,Ā according to a survey conducted by Spherix Global Insights. Also, COVID-19Ā not…
September 10, 2020 News by Marta Figueiredo, PhD #MSVirtual2020 – Ponesimod Superior to Aubagio in Delaying Disability Progression in Relapsing MS, Trial Data Show Janssen Pharmaceuticalsā investigational oral therapy ponesimod is superior to Sanofiās Aubagio (teriflunomide) in delaying disability progression in adults with relapsing multiple sclerosis (MS), according to exploratory analyses of OPTIMUM clinical trial data. These and other findings from Janssenās MS research program, including on the health…
March 23, 2020 Columns by Ed Tobias MS News that Caught My Eye Last Week: Coronavirus and DMTs, Gilenya and Pediatric MS, Ponesimod for RRMS, Cannabis for Spasticity I’m starting this week by linking to our Coronavirus COVID-19 Information section on the Multiple Sclerosis News Today Forums. My fellow moderator, John Connor, and I have been posting information there from our news writers and columnists about the evolving situation. Have You Tested Positive for Coronavirus…
March 20, 2020 News by Marisa Wexler, MS Janssen Seeks FDA Approval for Oral Ponesimod for Treating Relapsing MS Janssen has submitted an application to the U.S. Food and Drug Administration (FDA) asking for ponesimodĀ to be approved as an oral treatment for adults with relapsingĀ multiple sclerosis (MS). Ponesimod, formerly ACT-128800, is an experimental treatment that targets the proteinĀ sphingosine-1-phosphate…
March 12, 2020 News by Marisa Wexler, MS Ponesimod, Up for Approval, Shows ‘Clear Superiority’ Over Aubagio, Janssen Exec Says PonesimodĀ may soon be a new oral therapy for people with relapsing multiple sclerosis (MS) in Europe, and a filing for its approval in the U.S. is likely within weeks. Janssen Pharmaceuticals, its developer,Ā submitted an applicationĀ to the European Medicines Agency (EMA) inĀ early March, a first ponesimod filing…
March 5, 2020 News by Marisa Wexler, MS Janssen Asks EMA to Approve Oral Ponesimod to Treat Relapsing MS JanssenĀ has submitted an application toĀ the European Medicines Agency (EMA) asking that ponesimodĀ be approved as an oral treatment for adults with relapsing multiple sclerosis (MS) in the European Union. Ponesimod (formerly ACT-128800) is an experimental treatment that targets theĀ sphingosine-1-phosphate receptor…
September 18, 2019 News by Ana Pena PhD #ECTRIMS2019 ā Ponesimod Superior to Aubagio in Relapsing MS, OPTIMUM Trial Shows Actelion‘s ponesimod, an investigational oral treatment, is superior to Sanofi‘s Aubagio (teriflunomide) in lessening the frequency of relapses and easing fatigue symptoms in adults with active, relapsing multiple sclerosis (MS), results of the OPTIMUM trial show. These data will lay the ground for submissions…
August 5, 2019 Columns by Ed Tobias MS News That Caught My Eye Last Week: 3D and Early MRIs, Memory Training, Ponesimod Trial 3D Imaging of Brain Lesions May Spot Those Most Likely to Heal, Guiding Treatment These scientists are working to create a new diagnostic tool that would allow doctors to use an MRI to look at brain lesions in 3D. This would allow them to see the shape and surface…
July 30, 2019 News by Ana Pena PhD Ponesimod Fares Well in Phase 3 Trial for Relapsing MS, Janssen Announces JanssenĀ has announced positive, top-line results from its Phase 3 OPTIMUM study, testing the effectiveness and safety of ponesimod tablets, compared to Sanofi‘s Aubagio (teriflunomide), in adults with relapsing forms of multiple sclerosis (MS). The study met its primary goal ā a reduction in the…
November 8, 2017 News by Patricia Silva, PhD Global Phase 3 Trial of Oral Ponesimod Plus Tecfidera Enrolling Relapsing MS Patients Actelion is recruiting about 600 relapsing multiple sclerosis (MS) patients to a Phase 3 trial testing the addition of oral ponesimod to Tecfidera (dimethyl fumarate)Ā in people who continue experiencing relapses while on the treatment. Ponesimod works in a similar way to Novartisā Gilenya (fingolimod) ā making immune…
October 3, 2016 News by Patricia Silva, PhD Phase 3 Study to Test Oral Combination, Tecfidera and Ponesimod, to Treat Relapsing MS ActelionĀ announced that it will investigate the therapeutic potential of a new, oral combination therapy with ponesimod andĀ Tecfidera (dimethyl fumarate) asĀ a treatment for relapsing multiple sclerosis (RMS). The Phase 3 clinical study, being conducted underĀ a Special Protocol Assessment agreement with the U.S. Food and Drug Administration (FDA), aims to find…